Alnylam Pharma (ALNY) Ratios
Alnylam Pharma Ratios
MX:ALNY's free cash flow for Q3 2026 was $271.15M. For the 2026 fiscal year, MX:ALNY's free cash flow was decreased by $-69.83M and operating cash flow was $340.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 |
| Quick Ratio | 2.71 | 2.71 | 2.99 | 3.34 | 3.91 |
| Cash Ratio | 1.13 | 0.81 | 0.84 | 1.13 | 1.18 |
| Solvency Ratio | 0.09 | -0.05 | -0.10 | -0.29 | -0.26 |
| Operating Cash Flow Ratio | 0.36 | -0.01 | 0.11 | -0.70 | -0.92 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -0.07 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -126.49M | $ -877.61M | $ -1.07B | $ -1.01B | $ -246.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.65 | 0.34 | 0.37 | 0.27 |
| Debt-to-Equity Ratio | 1.62 | 40.89 | -5.92 | -8.34 | 1.70 |
| Debt-to-Capital Ratio | 0.62 | 0.98 | 1.20 | 1.14 | 0.63 |
| Long-Term Debt-to-Capital Ratio | 0.56 | 0.97 | 1.28 | 1.18 | 0.53 |
| Financial Leverage Ratio | 6.29 | 63.20 | -17.36 | -22.41 | 6.19 |
| Debt Service Coverage Ratio | 2.46 | -0.31 | -2.19 | -5.97 | -4.63 |
| Interest Coverage Ratio | 1.99 | -1.25 | -2.33 | -5.03 | -4.95 |
| Debt to Market Cap | 0.02 | 0.08 | 0.04 | 0.04 | 0.03 |
| Interest Debt Per Share | 11.69 | 22.60 | 11.42 | 12.13 | 9.63 |
| Net Debt to EBITDA | -0.60 | -9.94 | -1.91 | -0.49 | -0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.77% | 85.62% | 83.02% | 83.73% | 83.40% |
| EBIT Margin | 15.50% | -10.48% | -17.08% | -93.60% | -83.99% |
| EBITDA Margin | 17.00% | -7.95% | -14.12% | -89.31% | -78.36% |
| Operating Profit Margin | 13.51% | -7.87% | -15.43% | -75.68% | -83.93% |
| Pretax Profit Margin | 8.70% | -16.79% | -23.71% | -108.63% | -100.93% |
| Net Profit Margin | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
| Continuous Operations Profit Margin | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
| Net Income Per EBT | 97.09% | 73.71% | 101.55% | 100.37% | 100.08% |
| EBT Per EBIT | 64.43% | 213.34% | 153.63% | 143.55% | 120.25% |
| Return on Assets (ROA) | 6.32% | -6.56% | -11.49% | -31.90% | -23.41% |
| Return on Equity (ROE) | 39.76% | -414.62% | 199.53% | 714.91% | -144.99% |
| Return on Capital Employed (ROCE) | 14.33% | -5.79% | -9.86% | -28.26% | -24.04% |
| Return on Invested Capital (ROIC) | 13.74% | -4.06% | -9.72% | -27.84% | -23.72% |
| Return on Tangible Assets | 6.32% | -6.56% | -11.49% | -31.90% | -23.41% |
| Earnings Yield | 0.60% | -0.93% | -1.84% | -3.91% | -4.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.78 | 5.55 | 5.58 | 4.36 | 4.25 |
| Payables Turnover | 5.85 | 3.66 | 5.59 | 1.72 | 1.91 |
| Inventory Turnover | 8.19 | 4.12 | 3.48 | 1.31 | 1.62 |
| Fixed Asset Turnover | 5.25 | 3.24 | 2.52 | 1.40 | 1.15 |
| Asset Turnover | 0.75 | 0.53 | 0.48 | 0.29 | 0.23 |
| Working Capital Turnover Ratio | 1.58 | 1.09 | 0.93 | 0.51 | 0.41 |
| Cash Conversion Cycle | 58.63 | 54.62 | 104.98 | 150.46 | 119.54 |
| Days of Sales Outstanding | 76.42 | 65.80 | 65.44 | 83.72 | 85.85 |
| Days of Inventory Outstanding | 44.59 | 88.62 | 104.82 | 278.83 | 224.93 |
| Days of Payables Outstanding | 62.37 | 99.80 | 65.28 | 212.09 | 191.24 |
| Operating Cycle | 121.00 | 154.42 | 170.26 | 362.55 | 310.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 4.00 | -0.07 | 0.83 | -4.45 | -5.42 |
| Free Cash Flow Per Share | 3.55 | -0.33 | 0.34 | -5.04 | -6.06 |
| Dividend Paid and CapEx Coverage Ratio | 8.93 | -0.24 | 1.67 | -7.51 | -8.40 |
| Capital Expenditure Coverage Ratio | 8.93 | -0.24 | 1.67 | -7.51 | -8.40 |
| Operating Cash Flow Coverage Ratio | 0.41 | -0.00 | 0.08 | -0.41 | -0.64 |
| Operating Cash Flow to Sales Ratio | 0.14 | -0.00 | 0.06 | -0.52 | -0.76 |
| Free Cash Flow Yield | 0.89% | -0.14% | 0.18% | -2.12% | -3.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 166.38 | -107.99 | -54.31 | -25.57 | -23.55 |
| Price-to-Sales (P/S) Ratio | 14.03 | 13.36 | 13.08 | 27.88 | 23.79 |
| Price-to-Book (P/B) Ratio | 66.01 | 447.73 | -108.36 | -182.78 | 34.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 111.94 | -705.29 | 569.99 | -47.15 | -27.97 |
| Price-to-Operating Cash Flow Ratio | 99.40 | -3613.76 | 229.54 | -53.43 | -31.30 |
| Price-to-Earnings Growth (PEG) Ratio | -0.79 | 2.84 | 0.87 | -0.88 | 6.76 |
| Enterprise Value Multiple | 81.90 | -177.89 | -94.49 | -31.70 | -30.63 |
| Enterprise Value | 51.71B | 31.81B | 24.40B | 29.37B | 20.26B |
| EV to EBITDA | 81.90 | -177.89 | -94.49 | -31.70 | -30.63 |
| EV to Sales | 13.92 | 14.15 | 13.35 | 28.31 | 24.00 |
| EV to Free Cash Flow | 111.12 | -747.01 | 581.74 | -47.89 | -28.22 |
| EV to Operating Cash Flow | 98.68 | -3827.54 | 234.27 | -54.27 | -31.58 |
| Tangible Book Value Per Share | 6.02 | 0.53 | -1.77 | -1.30 | 4.97 |
| Shareholders’ Equity Per Share | 6.02 | 0.53 | -1.77 | -1.30 | 4.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.26 | -0.02 | -0.00 | -0.00 |
| Revenue Per Share | 28.35 | 17.61 | 14.64 | 8.53 | 7.13 |
| Net Income Per Share | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 |
| Tax Burden | 0.97 | 0.74 | 1.02 | 1.00 | 1.00 |
| Interest Burden | 0.56 | 1.60 | 1.39 | 1.16 | 1.20 |
| Research & Development to Revenue | 0.36 | 0.50 | 0.55 | 0.85 | 0.94 |
| SG&A to Revenue | 0.33 | 0.43 | 0.44 | 0.74 | 0.74 |
| Stock-Based Compensation to Revenue | 0.09 | 0.12 | 0.12 | 0.22 | 0.20 |
| Income Quality | 1.67 | 0.03 | -0.24 | 0.48 | 0.75 |
Currency in USD
